Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Heart failure-related quality-of-life impairment after myocardial infarction

P. Wohlfahrt, D. Jenča, J. Stehlik, V. Melenovský, J. Mrázková, V. Staněk, J. Kettner, M. Šramko, M. Želízko, V. Adámková, J. Piťha, J. Kautzner

. 2023 ; 112 (1) : 39-48. [pub] 20220318

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23004845

AIMS: Recent advances in therapy led to a significant decrease in mortality and morbidity after myocardial infarction (MI). However, little is known about quality of life (QoL) after MI. We examined heart failure (HF)-related quality-of-life (QoL) impairment, its trajectories, and determinants after MI. METHODS: Data from a single-center prospectively designed registry of consecutive patients hospitalized for MI at a large tertiary cardiology center were utilized. At 1 month and 1 year after hospital discharge, patients completed the Kansas City Cardiomyopathy Questionnaire (KCCQ). RESULTS: In total, 850 patients (aged 65 ± 12 years, 27% female) hospitalized between June 2017 and October 2020 completed KCCQ at 1 month after discharge. Of these, 38.7% showed HF-related QoL impairment (KCCQ ≤ 75). In addition to characteristics of MI (MI size, diuretics need, heart rate), comorbidities as renal dysfunction and anemia were associated with QoL impairment. Of the 673 eligible, 500 patients (74.3%) completed KCCQ at 1 year after MI. On average, QoL improved by 5.9 ± 16.8 points during the first year after MI (p < 0.001); but, in 18% of patients QoL worsened. Diabetes control and hemoglobin level at the time of hospitalization were associated with QoL worsening. CONCLUSION: Two out of 5 patients after MI present with HF-related QoL impairment. In addition to guideline-directed MI management, careful attention to key non-cardiac comorbidities as chronic kidney disease, anemia and diabetes may lead to further augmentation of the benefit of modern therapies in terms of QoL.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004845
003      
CZ-PrNML
005      
20230425171744.0
007      
ta
008      
230418s2023 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00392-022-02008-z $2 doi
035    __
$a (PubMed)35304902
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Wohlfahrt, Peter $u Department of Preventive Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. wohlfp@gmail.com $u Center for Cardiovascular Prevention, Charles University in Prague, First Faculty of Medicine and Thomayer Hospital, Videnska 800, 140 59, Prague, Czech Republic. wohlfp@gmail.com $1 https://orcid.org/000000032390526X
245    10
$a Heart failure-related quality-of-life impairment after myocardial infarction / $c P. Wohlfahrt, D. Jenča, J. Stehlik, V. Melenovský, J. Mrázková, V. Staněk, J. Kettner, M. Šramko, M. Želízko, V. Adámková, J. Piťha, J. Kautzner
520    9_
$a AIMS: Recent advances in therapy led to a significant decrease in mortality and morbidity after myocardial infarction (MI). However, little is known about quality of life (QoL) after MI. We examined heart failure (HF)-related quality-of-life (QoL) impairment, its trajectories, and determinants after MI. METHODS: Data from a single-center prospectively designed registry of consecutive patients hospitalized for MI at a large tertiary cardiology center were utilized. At 1 month and 1 year after hospital discharge, patients completed the Kansas City Cardiomyopathy Questionnaire (KCCQ). RESULTS: In total, 850 patients (aged 65 ± 12 years, 27% female) hospitalized between June 2017 and October 2020 completed KCCQ at 1 month after discharge. Of these, 38.7% showed HF-related QoL impairment (KCCQ ≤ 75). In addition to characteristics of MI (MI size, diuretics need, heart rate), comorbidities as renal dysfunction and anemia were associated with QoL impairment. Of the 673 eligible, 500 patients (74.3%) completed KCCQ at 1 year after MI. On average, QoL improved by 5.9 ± 16.8 points during the first year after MI (p < 0.001); but, in 18% of patients QoL worsened. Diabetes control and hemoglobin level at the time of hospitalization were associated with QoL worsening. CONCLUSION: Two out of 5 patients after MI present with HF-related QoL impairment. In addition to guideline-directed MI management, careful attention to key non-cardiac comorbidities as chronic kidney disease, anemia and diabetes may lead to further augmentation of the benefit of modern therapies in terms of QoL.
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a kvalita života $7 D011788
650    12
$a srdeční selhání $x epidemiologie $x terapie $7 D006333
650    _2
$a hospitalizace $7 D006760
650    12
$a infarkt myokardu $x komplikace $x epidemiologie $x terapie $7 D009203
650    12
$a anemie $7 D000740
655    _2
$a časopisecké články $7 D016428
700    1_
$a Jenča, Dominik $u Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
700    1_
$a Stehlik, Josef $u University of Utah School of Medicine, Salt Lake City, UT, USA
700    1_
$a Melenovský, Vojtěch $u Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
700    1_
$a Mrázková, Jolana $u Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
700    1_
$a Staněk, Vladimír $u Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
700    1_
$a Kettner, Jiří $u Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
700    1_
$a Šramko, Marek $u Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
700    1_
$a Želízko, Michael $u Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
700    1_
$a Adámková, Věra $u Department of Preventive Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Piťha, Jan $u Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
700    1_
$a Kautzner, Josef $u Department of Cardiology, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
773    0_
$w MED00155366 $t Clinical research in cardiology : official journal of the German Cardiac Society $x 1861-0692 $g Roč. 112, č. 1 (2023), s. 39-48
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35304902 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425171741 $b ABA008
999    __
$a ok $b bmc $g 1925126 $s 1191054
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 112 $c 1 $d 39-48 $e 20220318 $i 1861-0692 $m Clinical research in cardiology $n Clin Res Cardiol $x MED00155366
LZP    __
$a Pubmed-20230418

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...